– USA, TX – Maxwell Biosciences, a preclinical drug platform company focusing on first-in-class, small synthetic molecules that mimic natural peptides, today announced the appointment of Kate McKinley and Doug Boothe to its Board of Directors, adding experienced pharmaceutical industry CEOs with extensive commercialization, distribution and successful market access expertise to the board.
“I am pleased to welcome Kate and Doug to Maxwell’s Board of Directors. They bring proven track records and highly relevant expertise as we look to advance our CLAROMER drug discovery platform and potentially provide patients a new way to safely and effectively fight diseases caused by viruses, bacteria and fungi,” said Chairman and CEO Joshua McClure. “
About Kate McKinley
Kate McKinley has successfully executed regulatory and commercial strategies in cell therapy and small molecule oncology throughout her more than 20-year career in biotech. She brings a successful track record in rare/orphan designations; and urology, gynecology, immunology, and cardiology with both mature and novel products. She is the former CEO of Elevar Therapeutics, an integrated oncology-focused biopharmaceutical company, where she served from July 2021 until July 2022. She originally joined Elevar in 2019 as CCO, scaling and leading their global commercial, medical affairs, business development, manufacturing, supply chain, alliance management, and corporate communications organizations. Kate was previously VP of Marketing, Training, and Commercial Operations at Dendreon, where she was responsible for the first FDA-approved personalized immunotherapy to treat metastatic castration-resistant prostate cancer. Prior to Dendreon, she was U.S. Head of Sales at AbbVie, leading the oncology, urology and gynecology sales and field reimbursement organizations overseeing new product launch planning, rebranding initiatives, and market expansion strategies.
She graduated summa cum laude from The University of Tulsa with a Bachelor of Science in Business Administration in Marketing, Management and Psychology, and holds a Master of Business Administration in Marketing Strategy from the university’s Collins College of Business.
About Douglas S. Booth
Doug Boothe is the President and CEO of Akorn, a specialty pharmaceutical company. Prior to joining Akorn in January 2019, he was President of the U.S. Generics Division of Impax Laboratories, where he led a $600 million business and successfully expanded the market share of the generic epinephrine auto-injector Adrenaclick®. Doug previously was EVP and GM, Pharmaceuticals, at Perrigo, where he was responsible for product selection, R&D prioritization, financial and operational planning, and commercial sales and marketing operations. Earlier in his career, he was CEO of Actavis, a global generic pharmaceutical company that merged with Allergan in 2015.
He graduated with a Bachelor of Science in Mechanical and Aerospace Engineering from Princeton University and holds a Master of Business Administration in Management and Marketing from The Wharton School of the University of Pennsylvania.
About Maxwell Biosciences
Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops biomimetic therapeutics – synthetic compounds that mimic and improve upon natural peptides. Inspired by nature, these small molecules are created by Maxwell’s exclusive, first-in-class CLAROMER™ drug discovery platform. They have been shown to be effective in destroying viruses, bacteria, fungi and biofilms with a single compound, while safely avoiding healthy cells. This “One Drug for Many Bugs” technology has been shown to be well-tolerated in human tissues in vitro, and in multiple animal studies. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by numerous granted and pending patents and is led by a world-class team of experienced life science executives.
For more information: https://maxwellbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
